{"id":"W2257109151","doi":"10.1200/jco.2008.26.15_suppl.1026","title":"Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pertuzumab; Trastuzumab; Rash; Internal medicine; Clinical endpoint; Mucositis; Gastroenterology; Metastatic breast cancer; Phases of clinical research; Nausea; Oncology; Cancer; Clinical trial; Breast cancer; Chemotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium","status":"direct model label, unvalidated"}],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002696584,0.0002685499,0.002817177,0.0003805095,0.00007786016,0.000005912281,0.000240249,0.0002732747,0.00007956419],"category_scores_gemma":[0.001450103,0.0001769439,0.0003427194,0.000447778,0.0008861643,0.0001810744,0.00006367017,0.001302044,5.338517e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006182542,"about_ca_system_score_gemma":0.004740581,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003552867,"about_ca_topic_score_gemma":0.0001746211,"domain_scores_codex":[0.9932857,0.001008537,0.003685377,0.0003831583,0.001194054,0.0004431674],"domain_scores_gemma":[0.9939516,0.001569243,0.002517158,0.0002740108,0.0012469,0.0004411328],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7115776,0.04604619,0.03553932,0.0001711593,0.001112254,0.001000532,0.002852491,0.00001957381,0.0004336694,0.00000305375,0.00039279,0.2008514],"study_design_scores_gemma":[0.4098341,0.2403986,0.3460629,0.0009314812,0.0002317678,0.0005120689,0.0002333089,0.00007357451,0.0009734442,0.00001156211,0.0005900441,0.0001472002],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949093,0.000550485,0.000009960394,0.002539209,0.0002436857,0.00135657,0.0001293443,0.000005688503,0.0002556857],"genre_scores_gemma":[0.9954293,0.003108319,0.0007814906,0.0001441413,0.0003622393,0.00003752952,0.000005531209,0.00003909829,0.00009231429],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3105236,"threshold_uncertainty_score":0.8409588,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1342789399803358,"score_gpt":0.4944826051640951,"score_spread":0.3602036651837593,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}